Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Paediatrics
  4. Back
  5. Emergency Medicine (Paediatric)
  6. Adrenal suppression secondary to exogenous glucocorticoid - guidance for children on long term steroid therapy (511)
May 2025 RDS newsletter now available. Expand this announcement to view.

Welcome to the May 2025 update from the RDS team

1.     RDS deployments

Three small-scale releases took place during April and May, including the following fixes and improvements:

  • Applying moderate severity security patch to Umbraco.
  • Fixes to:
    • Random ordering of tiles on mobile app
    • Simultaneous issuing of multiple copies of content review alerts
    • Content display on mobile app for the left hand menu navigation option
  • Whitelisting of Jotforms outcomes pages so that recommendations for action can be displayed following completion of a form or calculation.

2.     RDS performance

Two short outages took place on the mornings of 12th and 22nd May. Tactuum is still investigating the root cause and will report on this shortly.

3.     Redesign of Gentamicin and Vancomycin calculator interfaces

New designs have been produced which make the health board name and calculator title clear to the user on these calculator pages, with a warning message and link to ensure users access the right calculator for their board. These designs have been implemented in a test environment and are now under review.

4.     RDS Redesign, archiving and version control

We now plan to release at end of July 2025 the following major enhancements:  redesigned Right Decision Service homepage, new search and browse interface, upgraded archiving and version control, and capability to edit content adopted from the Shared Content Library. We will provide slides and demos in advance of the release to introduce users and editors to the new functionality.

5. Training sessions for RDS editors

Introductory webinars for RDS editors will take place on:

  • Monday 16 June 12.30-1.30 pm
  • Tuesday 24 June 3.45-4.45 pm

Running usage statistics reports using Google analytics

  • Wednesday 11th June: 2-3pm

 To book a place on any of these webinars, please contact Olivia.graham@nhs.scot providing your name, role, organisation, title and date of the webinar you wish to attend.

6.New RDS toolkits

The following toolkits were launched during March 2025:

7.New RDS developments

Work is progressing on a number of decision support systems that are part of the wider Right Decision Service platform, beyond the web and mobile apps:

  • The Patient Reported Outcome Measures system. A minimum viable product version will be available for functional testing by key stakeholders at end of July.
  • Pharmacogenomics decision support as an extension of the current high risk prescribing decision support integrated with primary care electronic health record systems. This is part of a European research and innovation project.
  • Planned Date of Discharge decision support system to be tested in NHS Lanarkshire. Will undergo user acceptance testing in July with a view to piloting from November.

8. Implementation projects

Public library services in Inverclyde, East Renfrewshire, Glasgow Life, Angus, Falkirk and Stirling have come forward to work with the RDS team, the Scottish Library and Information Council and local Realistic Medicine leads, to develop their role in engaging citizens in Realistic Medicine. This includes promoting the Being a partner in my care app: Realistic Medicine Together. This provides tools and resources to support conversations about what matters to the person,  shared decision-making and self-management.

 

If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

 

 

 

Adrenal suppression secondary to exogenous glucocorticoid - guidance for children on long term steroid therapy (511)

Warning

Objectives

This document provides guidance on management and monitoring of children on long term steroids who at risk of secondary adrenal suppression.

There is limited evidence in the area of monitoring/management during the discontinuation of long term steroid therapy. This guidance is developed to ensure safe practice, as there have been reported fatalities secondary to adrenal suppression.

Background to condition

Oral glucocorticoids (steroids) are widely used for their anti-inflammatory and immunosuppressive properties in many conditions eg duchenne muscular dystrophy, juvenile idiopathic arthritis/chronic childhood rheumatic conditions, inflammatory bowel disease, atopic conditions, nephrotic syndrome, childhood cancers, solid organ transplant etc

Physiological cortisol production is equivalent to approximately 10 mg/m2/day Hydrocortisone.

Steroid equivalence for glucocorticoid activity

1 mg Prednisolone= 4 mg hydrocortisone

1 mg Triamcinolone= 4mg hydrocortisone

1 mg Methylprednisolone = 5mg hydrocortisone

1 mg Deflazacort= 6 mg hydrocortisone

1 mg Dexamethasone= 25 mg hydrocortisone 

Who is at risk?

  1. All pharmacological doses of oral steroid used clinically for treatment in current paediatric clinical practice are greater than physiological dose. Therefore, children treated with higher than physiological dose of steroid (> 2.5 mg/m2/day Prednisolone or > 10 mg/ m2/day hydrocortisone or equivalent) for greater than 4 weeks maybe at risk of secondary adrenal suppression. 

  2. Continuous treatment for > 6 months will increase the risk. Children treated for > 12 months are at very high risk. 

  3. Concurrent treatment with other forms of steroid eg intra-articular, inhaled, topical, nasal, eye drops will increase the risk. (Refer to separate guidance for monitoring of children on inhaled steroid)

  4. Repeated use of intra-articular, inhaled, topical, nasal, eye drop steroids may also lead to adrenal insufficiency.  

The absence of cushingoid appearance does not mean that the patient is not at risk of adrenal suppression. However, if a child has cushingoid appearance, he/she should be assumed to have adrenal suppression. The absence of clinical symptoms of adrenal insufficiency does not mean that the patient is not at risk of adrenal suppression. 

Flow chart summary of management and monitoring of children on long term oral steroid therapy

All children commencing long term steroid or treated for > 6 months  



Steroid card/sick day plan (IM hydrocortisone education ideally)


If planning to discontinue long term steroid therapy



Wean treatment dose of steroid down to  
Prednisolone equivalent of 2.5 mg/m2/day over 4-6



Convert to oral hydrocortisone 10 mg/m2/day in three divided doses
Need to double dose of oral hydrocortisone (48 hours) during acute illness
Inform endocrine team (page 18301) or link endocrine consultant for specialty

 

Synacthen test after at least 8 weeks of oral hydrocortisone 
- Omit hydrocortisone the night before and morning of synacthen test 
- Recommence hydrocortisone until results of synacthen test available 
- Inform endocrine team if peak cortisol to synacthen ≤ 450 nmol/L 
and review in endocrine clinic

 

Management of children maintained on prolonged (> 6 months) oral steroid (> 2.5 mg/m2/day Prednisolone or > 10 mg/m2/day hydrocortisone equivalent)

An investigation of adrenal axis in this group of children whilst they remain on steroid is not necessary as these children have definite secondary adrenal insufficiency. The treatment dose of steroid of is greater than double the physiological dose.  

However, all children on oral steroid and who are likely to remain on treatment for > 6 months should be:

  1. Issued with steroid card/medical bracelet. 
  2. Counselled not to discontinue steroid abruptly. 

  3. Provided with sick day plan during intercurrent illnesses, especially when unable to tolerate steroids due to vomiting. 

    Ideally, families should be provided with education to be able to inject IM hydrocortisone in such instances or have immediate access to IM hydrocortisone as per the recommendations of the British Society for Paediatric Endocrinology & Diabetes (BSPED) and the Scottish Paediatric Endocrine Group (SPEG). 

  4. Provided with IV hydrocortisone cover during acute inpatient admission, surgery, and general anaesthetic.  

    (a)Stress doses of oral steroid (ie double of oral dose of steroid for 2 days) during mild acute illness are not needed for children on≥ 2.5 mg/m2/day Prednisolone or ≥ 10 mg/m2/day hydrocortisone equivalent.

    (b)For children managed with on/off steroid therapy (eg 10 days on/off etc), an oral sick day plan may be needed during the period the child is not on steroid treatment. This could be in the form of 48 hours of usual steroid therapy or in the form of oral hydrocortisone 20 mg/m2/day TDS.

    (c)Stress doses of oral steroid (ie double of oral dose of steroid for 2 days) during mild acute illness are needed for children on≤ 2.5 mg/m2/day Prednisolone or ≤ 10 mg/m2/day hydrocortisone equivalent. 

Dose of Regular Steriod

Sick day/stress dose

≥ 5 mg/m2/day Prednisolone 

Or

≥ 10 mg/m2/day hydrocortisone equivalent*.

 

No additional increase in dose

≤ 2.5 mg/m2/day Prednisolone 

or 

≤ 10 mg/m2/day hydrocortisone equivalent*.

 

Double dose of steroids for 48 hours 

*see equivalent doses here 

Management of children discontinuing prolonged (> 6 months) oral steroid

Normal endogenous cortisol secretion resumes in 6-8 weeks in most cases although normal secretion may not resume for 6-12 months especially in those following prolonged periods of oral steroid treatment (> 12 months) and/or those who have had concurrent treatment with other forms of steroid (eg topical, inhaled or intra-articular etc). 

42% of children who discontinued long term oral steroid therapy have an abnormal response to synacthen test despite a weaning regime. No clinical or biochemical factors could predict those with abnormal response (Wildi-Runge S et al J Pediatr 2013).   

All children should be:

  1. Issued with steroid card/medical bracelet.

  2. Counselled not to discontinue steroid abruptly.

  3. Provided with sick day plan during intercurrent illnesses, especially when unable to tolerate steroids due to vomiting. 

    Ideally, families should be provided with education to be able to inject IM hydrocortisone in such instances or have immediate access to IM hydrocortisone as per the recommendations of the British Society for  Paediatric Endocrinology & Diabetes (BSPED) and the Scottish Paediatric Endocrine Group(SPEG).

  4. Provided with IV hydrocortisone cover during acute inpatient admission, surgery, and general anaesthetic. 

 

1. Discontinuing steroid (Duration of treatment > 6 months) 

These children are at a higher risk of secondary adrenal suppression and therefore a longer recommended period of weaning may be necessary.  

Wean steroid dose down to a physiological dose  equivalent  (ie 2.5 mg/m2/day Prednisolone or equivalent) in the duration that symptoms of the underlying condition permits (or at least 4-6 weeks), then change to hydrocortisone (10 mg/m2/day Hydrocortisone) as it has a shorter half-life and aids in the recovery of adrenal function. Inform endocrinology team. Once the child has been on physiological dose of oral hydrocortisone for at least 8 weeks, perform synacthen test.

Omit evening and morning dose of hydrocortisone to perform synacthen test. Recommence oral hydrocortisone after synacthen test until results of synacthen test available. 

Consider discussing weaning plan with endocrinology earlier for children who have been treated with steroid for > 12 months or younger children (< 5 years). 

 

2. Discontinuing steroid (Duration of treatment ≤ 6 months or intermittent treatment eg multiple short courses) 

Some of these patients may be at risk of adrenal suppression.

For safe practice, we recommend the consideration of  synacthen test in the children in this group when off steroids for at least 2 weeks or just before next steroid treatment if there are symptoms of suggestive of adrenal insufficiency or other clinical concerns*. 

* Symptoms of adrenal insufficiency include:

  • Significantly tired/lethargy
  • Weight gain/weight loss
  • Multiple and increased frequency of intercurrent illnesses (Taking longer to recover) 

 

INTERPRETATION OF SYNACTHEN TEST

1. Peak synacthen > 450nmol/L

Normal

  • No need for further investigations unless clinical concerns. 

2. Peak synacthen 300-450nmol/L 

Mild to moderate adrenal suppression 

  • Inform endocrinology and refer to endocrine clinic.
  • Sick day plan
  • Stress dose oral hydrocortisone (double oral dose for 2 days) for mild acute illness. 
  • IM hydrocortisone for vomiting illness.
  • Repeat synacthen test in 6 months if remain off steroids. 

3. Peak synacthen < 300 nmol/L 

Significant adrenal suppression 

  • Inform endocrinology and refer to endocrine clinic.
  • Replacement and Sick Day Plan
  • Recommence oral hydrocortisone at physiological dose 10 mg/m2/day.
  • Stress dose oral hydrocortisone (double oral dose for 2 days) for mild acute illness.
  • IM hydrocortisone for vomiting illness.
  • Repeat synacthen test in 6-12 months if remain off steroids.

 

Emergency management of adrenal crisis

INTRAMUSCULAR HYDROCORTISONE REGIME FOR VOMITING ILLNESS (FOLLOW SICK DAY PLAN, PARENTS SHOULD BE AWARE)

Age

IM Hydrocortisone Dose

<6months

12.5mg

6 months-5years

25mg

5-10years

50mg

>10years

100mg

 

Hospital management of children with secondary adrenal suppression during severe illness

Management of children with secondary adrenal suppression due to steroid treatment during acute illness requiring admission is the same as any child with primary adrenal insufficiency. 

If severely unwell,

  • Check blood sugar and urea & electrolytes including full blood count
  • If capillary glucose <3mmol/l give 2-4 ml/kg of 10% dextrose
  • Fluid bolus may also be required (10-20ml/kg 0.9% saline) if indicated.
  • Give hydrocortisone bolus and start infusion (table below).  
  • Give bolus IV hydrocortisone if unwell even if IM hydrocortisone has been given at home.
  • Start IV maintenance fluids + deficit (with dextrose containing fluids)
  • Consider double dose hydrocortisone therapy once able to tolerate oral medications

Child may already be on double hydrocortisone therapy and possibly received intramuscular dose of hydrocortisone at home. 

Beware clinical improvement may be due to IM hydrocortisone.

If the child has received a hydrocortisone bolus, either at home or in hospital, we would advise at least overnight admission. 

Age

 

Hydrocortisone Bolus [if no IM dose given]

 

Hydrocortisone infusion

[50mg hydrocortisone in 50mls 0.9%saline]

<6months

12.5mg

1ml/hr

6 months-5years

25mg

1ml/hr

5-10years

50mg

2ml/hr

>10years

100mg

3ml/hr

 

Management of children with secondary adrenal suppression during surgery

  • For minor surgery/procedure (< 1 hour), bolus IV hydrocortisone should be given at induction (See table above).

  • When the child is able to eat and drink, give usual steroid dose or stress dose oral steroid for the next 24-48 hours (hydrocortisone 20 mg/m2/day or equivalent) if usually on hydrocortisone or equivalent of 10 mg/m2/day.

  • Beware of children undergoing tonsillectomy, as may not tolerate intake and may need hydrocortisone infusion. 

  • For major surgery especially major bowel surgery where the child has to be NBM after surgery, bolus hydrocortisone should be given at induction and a hydrocortisone infusion commenced.

  • When the child is able to eat and drink, give usual steroid dose or stress dose oral steroid for the next 48 hours (hydrocortisone 20 mg/m2/day or equivalent). 

Editorial Information

Last reviewed: 25/05/2022

Next review date: 25/05/2023

Author(s): Jarod Wong.

Version: 3

Approved By: Paediatric Drugs & Therapeutic Committee

Document Id: 511